Objective To identify genetic loci associated with features of histologic severity of nonalcoholic fatty liver disease in a cohort of Hispanic boys.
Results
The median age and body mass index z-score were 12.0 years (IQR, 11.0-14.0) and 2.4 (IQR, 2.1-2.6), respectively. The nonalcoholic fatty liver disease activity score (scores 1-4 vs 5-8) was associated with SNP rs11166927 on chromosome 8 in the TRAPPC9 region (P = 8.7 -07 ). Fibrosis stage was associated with SNP rs6128907 on chromosome 20, near actin related protein 5 homolog (p = 9.9 -07
). In comparing our results in Hispanic boys with those of previously reported SNPs in adult nonalcoholic steatohepatitis, 2 of 26 susceptibility loci were associated with nonalcoholic fatty liver disease activity score and 2 were associated with fibrosis stage.
Conclusions In this discovery genome-wide association study, we found significant novel gene effects on histologic traits associated with nonalcoholic fatty liver disease activity score and fibrosis that are distinct from those previously recognized by adult nonalcoholic fatty liver disease genome-wide association studies. (J Pediatr 2017; 190:100-7) . N onalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children and adults in the developed world. The histologic expression of the disease ranges from steatosis to steatohepatitis, to marked fibrosis and cirrhosis. Multiple factors contribute to disease progression, including environmental influences such as dietary intake, physical activity, and genetic predisposition. Genome-wide association studies (GWAS) have shown that the heritability of complex traits and complex disorders, such as NAFLD, may be due to multiple genes of small effect size. 1 The genetic susceptibility in NAFLD merits investigation given the implications for disease progression associated with unique pathogenic variants.
The basis for a genetic component in NAFLD is well-founded. Familial clustering, epidemiologic data, and twin studies demonstrate that inherited factors influence the likelihood and severity of pediatric nonalcoholic steatohepatitis (NASH). 2 The heritability of fat fraction as a continuous trait and the heritability of steatosis and fibrosis have been demonstrated using noninvasive means. 3, 4 Furthermore, striking ethnic variability found in the prevalence of NAFLD provides further evidence for significant genetic factors impacting pathogenesis. 5, 6 Several large-scale GWAS have sought to identify common genetic variants associated with NAFLD susceptibility and disease progression. These studies have consistently reported strong associations between the nonsynonymous amino acid substitution I148M in the patatin-like phospholipase domain containing 3 gene (PNPLA3), that encodes a triacylglycerol lipase expressed in adipocytes, with the risk of steatosis and steatohepatitis. 7, 8 Additionally, single nucleotide polymorphisms (SNPs) near TM6SF2 and PPP1R3B have been associated with hepatic steatosis and variants within or near NCAN, GCKR, and LYPLAL1, in addition to PNPLA3, emerged in a study relating these variants to severity of lobular inflammation and fibrosis. 9 Smaller scale GWAS of similar sample size in adults provided additional evidence that genetic variants seen in adults with NAFLD were associated with key histologic features. 10 The I148M variant of PNPLA3, the major genetic risk factor for NASH identified in adults, also is associated with liver enzyme elevations and degree of steatosis in obese children. [11] [12] [13] [14] Epidemiologic data not only points to a genetic component of the disease but also highlights the influence of sex hormones. NAFLD is consistently more prevalent in boys than in girls, which suggests that sex hormones are associated with the predilection for pediatric NAFLD. 15 Given the aforementioned effects from sex hormones and ethnicity, we aimed to minimize noise from heterogeneity in ethnicity and sex by focusing on Hispanic boys.
Methods
All Hispanic boys enrolled in the NASH Clinical Research Network (CRN) in the NAFLD Database I Study (n = 234) were included in this discovery cohort. This multicenter, prospective, longitudinal cohort was established in 2002 by the National Institute of Diabetes and Digestive and Kidney Diseases and contains >4400 subjects. Clinical and histologic features of database participants have been described by Patton et al. 16 These subjects met exclusion criteria for any other potential contributors to fatty liver disease. From the pediatric cohort, all Hispanic boys (2-17 years of age) with liver biopsies were included. Biopsy specimens were reviewed and scored centrally by the NASH CRN Pathology Committee. Specimens were scored according to the histology scoring system established by the NASH CRN. 17 The Institutional Review Boards at each participating center approved the protocols in addition to the NASH CRN Steering Committee. All parents provided consent for their child's participation and all children >7 years of age provided assent.
Genotyping was performed at the Medical Genetics Institute at Cedars-Sinai Medical Center using Illumina OmniExpress chips technology (HumanCNV370-Quadv3 BeadChips; Illumina, San Diego, California 18, 19 ). Genotypes were determined based on clustering of the raw intensity data for the 2 dyes using Illumina BeadStudio software. Two samples performed in duplicate yielded 100% concordance. Quality controls were performed on the 234 samples and 624 297 SNPs using PLINK. 20 For SNPs on the 22 autosomal chromosomes, we applied the following filter criteria: genotype missing rate >0.02, minor allele frequency <0.05, Hardy-Weinberg equilibrium P < 10 -6 , and heterozygosity >0.53. We also performed quality control at an individual level to check for missing rate and cryptic relatedness (π ). Cryptic relatedness refers to unknown more recent relatedness (as opposed to distant relatedness) and includes family relationships such as grandparent-grandchild and full sibling pairs. Populationbased association studies assume independent (unrelated) individuals.
We observed no sample with a missing rate of >0.02, but found 22 pairs of samples withˆ. π ≥ 0 25. Principal component analysis was then carried out using EIGENSTRAT (Harvard, Boston, MA) 21 to examine potential population stratification among our study samples. Four samples were identified as population outliers (spurious component analysis). We thereafter excluded 26 samples (22 cryptic relatedness and 4 principal component analysis outliers) from further association analysis. To adjust for potential population stratification, we included the first 2 principal components as covariates in the model of association analysis. The final dataset for the association analysis after quality controls had 208 samples.
We evaluated the ability to detect an association between an SNP and nonalcoholic fatty liver disease activity score (NAS [NADH CRN, Bethesda, MD]) by power calculation implemented in QUANTO version 1.2.4. Based on the mean and SD of NAS (4.27 ± 1.69) in a preliminary sample of patients enrolled into the NAFLD Database Study, we assessed the power using 208 independent individuals under an additive genetic model. For detectable effect size of >0.8, a sample size of 208 will have enough power (>0.83) to identify the association under additive model with minor allele frequency of >0.1.
Statistical Analyses
The GWAS was performed to identify genetic factors associated with specific features or combinations of liver histology. End points of interest in this study were NAS, definite NASH as defined by prespecified histologic criteria, and fibrosis stage. NAS ranges in score from 1 to 8. In our association analysis, NAS was analyzed as a qualitative (binary) trait by comparing a NAS of ≤4 with a NAS of >4. This cutpoint was chosen based on clinical because a NAS of >4 has been shown to correlate with the presence of NASH. 22 Fibrosis stage was analyzed as a quantitative trait based on stage, which ranged from 0 to 4. The association between the endpoints of interest and each SNP was evaluated in the model with the first 2 PCs as covariates. For each SNP, association analyses were run both under an additive and a dominant genetic model using the PLINK software. Logistic regression analysis was carried out for NAS and definite NASH and linear regression analysis was run for fibrosis grade. We further examined SNPs with P < 10 -5 from the GWAS (referred below as "top SNPs"). We used SCAN (SNP and CNV Annotation Database; available from: http://www.scandb.org/newinterface/about.html) to annotate genes for the top SNPs.
We also examined previously identified genetic loci associated with NAFLD in adult populations to determine if they generalize to this group of Hispanic boys. We studied the 26 susceptibility loci that were reported in the previously published GWAS. 10 Proxy SNPs found by SNAP 23 were used for SNPs not included in our current study. SNPs with a P value of <.05 in our analysis provided the degree of confirmation for the association with NAS and/or fibrosis grade.
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With the association results obtained from additive and dominant genetic models, we generated Manhattan plots showing the − ( ) log P 10 value along with the 22 autosomal chromosomes for NAS and fibrosis grade. We also generated regional plots for the region around the top association signals. The regional plot shows association P values (−log10 scale) on the vertical axis along with recombination rates and all candidate genes in the region around the top SNPs (250 kB bilaterally) using LocusZoom (University of Michigan, Ann Arbor, MI). 24 The plots also show the pairwise linkage disequilibrium pattern with the most strongly associated SNP, which has the smallest P value in the region. SNPs in the plot are colored based on their r 2 with the most strongly associated SNP. We calculated quantile-quantile plots for NAS and fibrosis using an additive model to assess for normality and these are shown (Figure 1 ; available at www.jpeds.com).
Results
A total of 234 overweight or obese Hispanic boys were included in the GWAS. Subjects with cryptic relatedness were excluded (n = 22), as were those with a spurious component analysis (n = 4), leaving 208 subjects who met inclusion and exclusion criteria. Clinical and laboratory characteristics of the 208 subjects included are shown in Table I . The median age was 12 years (IQR, [11] [12] [13] [14] . Median body mass index (BMI), waist-to-hip ratio, and serum aminotransferase values are elevated and consistent with that reported previously in pediatric NAFLD, along with elevated metabolic parameters of median hemoglobin A1c, glucose, and insulin. With regard to diagnostic patterns, 22% of subjects had a definite NASH pattern (1 group), 53% with borderline NASH (zone 3 or 1), and 23% with NAFLD but no NASH (grouped together). The borderline zone 1 pattern is unique to children and may indicate an age-specific entity with a unique pathogenesis and natural history. 25 The median NAS was 4 (IQR, [3] [4] [5] . The majority of subjects had some degree of fibrosis, with 18% demonstrating advanced fibrosis.
The results are depicted in the Manhattan plots ( Figure 3 , A], and 6.06 × 10 -7 with a dominant model). In addition, we found SNP rs1544175 on chromosome 1 in the Olfactory Receptor 2T4 gene met the selection criterion with p-value (Pd = 9.61 × 10 -6 ; Pa = 1.14 × 10 -4 ). However, given a median score of 4 (IQR, 3-5), we undertook a secondary binary appropriation of NAS < 3 vs NAS ≥ 5, excluding the midrange to avoid misclassification. Two SNPs were associated with NASH (defined as a binary trait, definite vs borderline) on logistic regression: SNP rs6571631 on chromosome 14 near Rho guanine nucleotide exchange factor ARHGEF40 (P = 6.51 × 10 -6 ) and rs6660749 on chromosome 1 near C1orf94 (8.21 × 10 -6 ). Table III presents the SNPs associated with fibrosis stage. Using an additive model, 7 SNPs associated with fibrosis grade, including rs11465670 on chromosome 2 in the interleukin-18 receptor accessory protein (IL18RAP) gene, rs688020 on chromosome 7 in sidekick homolog 1 (SDK1) gene, rs3935794 on chromosome 11 in v-ets erythroblastosis virus E26 oncogene homolog 1 (ETS1) gene, rs12942311 on chromosome 17 in RAB37 gene, and 3 SNPs (rs6128907, rs6124026, and rs6128918) on chromosome 20 in the ARP5 actin-related protein 5 homolog (ACTR5) gene (Figure 2, B) . When we tested the association under a dominant genetic model, association with SNPs rs3935794 and rs11465670 remained with P <10 In the latter analysis, we also found an association with rs17223990 on chromosome 2, rs231957 on chromosome 6 in the NADPH oxidase 3 (NOX3) gene, rs3935794 on chromosome 11 in the ETS1 gene, rs7202949 on chromosome 16, and rs454006 on chromosome 19 in the Protein Kinase C Gamma (PRKCG) gene.
To inspect associated regions in more detail, we generated regional plots that provided association analysis results along with recombination rates and all candidate genes in the region around the top SNPs (250 kilobases on each side) using the LocusZoom. 21 Most of the regional plots indicate a series of SNPs contributed to the association at each locus (Figure 3) .
Generalization Study for the Previously Published GWAS SNPs
Results in the current study were compared with results reported in our previous study of adult patients with NASH, as Chr, chromosome; MAF, minor allele frequency. . P values were obtained by association analysis when including age and BMI z-score as covariates and assuming an additive genetic model. The y-axis on the right shows recombination rate (cM/Mb). The r 2 shows measure of the linkage disequilibrium between this SNP and target SNP. The genes TRAPPC9 and KCNK9 are located in the region as indicated at the bottom of the figure. B, Regional plot for fibrosis. The -log10(P value) from association analysis is show for all SNPs in the region around the top SNP rs6128907 for fibrosis. The x-axis shows position of the SNPs along chromosome 20; the y-axis in the left gives -log10(P value). P values were obtained by association analysis when including age and BMI z-score as covariates and assuming an additive genetic model. The y-axis on the right shows recombination rate (cM/Mb). The r 2 shows measure of the linkage disequilibrium between this SNP and target SNP. The genes located in the region of ACTR5 are as indicated at the bottom of the figure. THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 190 well as examining significant SNPs previously reported. [7] [8] [9] [10] [11] [12] [13] [14] We examined association results for 26 susceptibility loci in our Hispanic boys cohort (Table IV; available at www.jpeds.com). Two out of the 26 SNPs evaluated were found to be associated (P value ≤.05) with NAS: rs2228603 located within the Neurocan (NCAN) gene on chromosome 19 which codes for the neurocan core protein and rs7324845, located within the intron of the lymphocyte cytosolic protein-1 (LCP1) gene on chromosome 13, encoding an actin-binding protein. Variants in NCAN had been previously associated with the existence of hepatic steatosis, 9 inflammation and fibrosis 26 and variants in LCP1 were associated with NAFLD in adolescents. 27 Five of the 26 SNPs were found to be associated with fibrosis grade when the additive model was used: rs2228603 (Pa = .013) encoding NCAN as aforementioned and rs2499604 (Pa = .0033) located on chromosome 1 and previously associated with elevated alanine aminotransferase values in NAFLD. 10 Interestingly, variant rs5764034 encoding PNPLA3 and rs2074301 and rs2074303 encoding TM6SF2 were three of the variants associated with fibrosis that have been previously reported in adult GWAS for NAFLD. 9 Discussion NAFLD is largely defined by histology. We undertook this discovery GWAS to investigate potential genetic influences relating to histologic components of pediatric NAFLD in a discovery cohort of Hispanic boys with biopsy-proven NAFLD. Hispanic boys with NAFLD serve as an ideal discovery cohort given their higher propensity for NAFLD risk factors such as obesity, diabetes, and other aspects of the metabolic syndrome. [28] [29] [30] [31] The genetic homogeneity of this population, primarily Mexican Americans, increases power to detect associations of interest that would require greater sample size in a more heterogeneous sample. 32 Notably, alleles of patatin like phospholipase domain containing 3 (PNPLA3) with extensive prior associations with NAFLD were not associated with NAS in this study and fibrosis only at the P = .010 level. Likely, this is due to relative homogeneity within this cohort for the PNSPLA3 susceptibility variants.
This GWAS suggests novel associations using histologic parameters in Hispanic boys; however, the threshold for these associations is variable and depends on the quality of results, potential for mechanistic association, sample size, and minor allele frequency (ours chosen to limit spurious results). Novel variants found in our study included significant variants associated with NAS and fibrosis. Specifically, SNPs within the C8orf17/potassium channel, subfamily K, member 9 (TRAPPC9) gene locus on chromosome 8 were associated with NAS and SNPs within the ARP5 actin-related protein 5 homolog (ACTR5) gene locus on chromosome 20 were associated with fibrosis. The role of TRAPPC9 in NAFLD is unknown. Our association between 4 variants within chromosome 8 and the NAS in the intron regions of TRAPPC9 are novel. TRAPPC9 functions as an activator of nuclear factorkB through increased phosphorylation of the IKK complex. 33 Mutations in TRAPPC9 have been associated with autosomalrecessive mental retardation. [34] [35] [36] No prior associations with NAFLD in adults or pediatric populations have been described. The role of ACTR5 is thought to be one of a chromatin remodeling complex involved in transcriptional regulation, DNA replication, and probably DNA repair. 37, 38 Its role in hepatic fibrosis also has not been reported.
Previous work has been done with regard to the genetic variants associated with histologic changes in children with NAFLD. In a study of 118 Italian children with histologically proven NAFLD, based on prior work that showed some hepatoprotective effects of the cannabinoid receptor in children with steatosis, a functional variant, the CB2 Q63R polymorphism, was associated with severity of inflammation (P = .002) and the presence of NASH (P = .02), although it was not associated with steatosis or fibrosis. 39 Negatively associated with fibrosis (P = .012) was the rs13412852 TT genotype of LPIN1, independent of PNPLA3 genotype (previously mentioned as associated with hepatic steatosis) as well as clinical risk factors of age, waist circumference, hyperglycemia, or alanine aminotransferase. This variant was also associated with a lower NAS severity (P = .026).
40 LPIN1 is involved in the metabolism of phospholipids and triacylglycerol; it is required for adipogenesis and lipid flux between adipose tissue and the liver. In the liver it also acts as an inducible transcriptional coactivator to regulate fatty acid metabolism. As opposed to the independent effects of LPIN1, in 2012 Santoro et al reported that the rs1260326 variant in the glucokinase regulatory protein (GCKR) was associated with fat accumulation (detected by proton nuclear magnetic resonance, not histology) in the liver together with PNPLA3 to increase susceptibility in obese youths. 41 All prior pediatric genetic studies highlight preselected candidate variants in pathways known to be involved in the development of NAFLD: lipid biosynthesis and metabolism or glucose metabolism.
Our study selected a group of individuals with similar ethnicity, BMI z-score, sex, and age range. This strategy serves to minimize haplotypes that would be present in a larger study of varied ethnic groups. Although this is a strength for a GWAS of this size, the lack of a control group may have led to lack of association with previously reported SNPs related to NAFLD. A major limitation is the lack of validation for this discovery cohort. Other limitations include the lack of functional variants identified and an inability to determine genetic risk for Hispanics relative to non-Hispanics given the understandable lack of healthy controls. Additional clinical limitations include variation in time points between the time of biopsy and the collection of blood for DNA (range, approximately 6 months to 2 years; median, 4.5 months) and the inability to control for lifestyle factors such as diet and physical activity. Generalizability to girls and adults is also limited.
This study highlights possible associations between variants and histologic findings within a well-characterized disease state, but the functional implications of these variants is unknown, as is the mechanism by which these variants are implicated in the development or progression of NAFLD. Therefore, future directions should include validation cohorts of nonHispanic children, adolescents, and adults. Confirmation studies for the identified SNPs should be undertaken. By gaining a better understanding of the genetic causes of cellular changes as reflected histologically, we may better identify novel pathways of disease pathogenesis that are missed or minimized in adults, in part owing to the unique pattern of borderline zone 1 histology seen in a subset of children with NAFLD. As children with NAFLD develop into adults accumulating additional environmental influences, recognizing underlying genetic propensity adds significantly to informed interventions beyond recommended lifestyle changes. ■ 1 paints a picture that cholestyramine therapy not only treated pruritus in patients with liver disease but also reversed the declining liver function and growth delay in 2 of their 5 patients. The 5 patients in their study had an obstructive jaundice and subsequent pruritus. They benefitted from the use of increased doses of cholestyramine to achieve the desired outcome of decreasing pruritus. The mechanism was thought to be due to the reduction of serum bile acids.
Subsequent research has continued to demonstrate that buildup of bile acids in the liver do contribute to cholestasis and subsequent liver injury. 2 Pruritus remains difficult to treat despite evolving evidence regarding the pathogenesis of cholestatic pruritus. 3 In addition to cholestyramine, it has been shown that ursodiol, rifampin, naltrexone, and now more recently sertraline can be used to treat pruritus medically in patients with cholestasis. 4 Further research has supported the initial findings by Sharp et al in demonstrating the harmful effects of increased bile acids in cholestasis, as well as the use of cholestyramine as treatment for pruritus in such patients. It remains a topic of discussion with further research needed, given the negative impact that cholestatic pruritus has on patients' lives.
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Division of Gastroenterology, Hepatology, and Nutrition Cincinnati Children's Hospital Medical Center Cincinnati, Ohio Figure 1 . A, Quantile-quantile (QQ) plot for NAS (NAS ≤4 to NAS >4), grouped using an additive genetic model. The -log10 (P value) of observed. B, QQ plot for fibrosis, grouped using an additive genetic model. The -log10 (P value) of observed. 
